

Published in final edited form as:

*Oncogene*. 2009 September 24; 28(38): 3380–3389. doi:10.1038/onc.2009.193.

## p21<sup>WAF1</sup> gene promoter is epigenetically silenced by CTIP2 and SUV39H1

T Cherrier<sup>1,7</sup>, S Suzanne<sup>1,7</sup>, L Redel<sup>1</sup>, M Calao<sup>5</sup>, C Marban<sup>1</sup>, B Samah<sup>2</sup>, R Mukerjee<sup>3</sup>, C Schwartz<sup>1</sup>, G Gras<sup>2</sup>, BE Sawaya<sup>3</sup>, SL Zeichner<sup>4</sup>, D Aunis<sup>1</sup>, C Van Lint<sup>5,8</sup>, and O Rohr<sup>1,6,8</sup>

<sup>1</sup>INSERM unité 575, Université de Strasbourg, Institut de Virologie, Strasbourg, France

<sup>2</sup>CEA UMRE-01, Service de Neurovirologie, Fontenay aux Roses, France

<sup>3</sup>Laboratory of Molecular Virology, Department of Neurology, School of Medicine, Temple University, Philadelphia, PA, USA

<sup>4</sup>Children's National Medical Center and Departments of Pediatrics and Microbiology, Immunology, and Tropical Medicine, Children's Research Institute, George Washington University, Washington, DC, USA

<sup>5</sup>Laboratory of Molecular Virology, Institut de Biologie et de Médecine Moléculaire (IBMM), University of Bruxelles (ULB), Gosselies, Belgium

<sup>6</sup>IUT Louis Pasteur de Schiltigheim, Schiltigheim, France

### Abstract

Mainly regulated at the transcriptional level, the cellular cyclin-dependent kinase inhibitor, CDKN1A/p21<sup>WAF1</sup> (p21), is a major cell cycle regulator of the response to DNA damage, senescence and tumor suppression. Here, we report that COUP-TF-interacting protein 2 (CTIP2), recruited to the p21 gene promoter, silenced p21 gene transcription through interactions with histone deacetylases and methyltransferases. Importantly, treatment with the specific SUV39H1 inhibitor, chaetocin, repressed histone H3 lysine 9 trimethylation at the p21 gene promoter, stimulated p21 gene expression and induced cell cycle arrest. In addition, CTIP2 and SUV39H1 were recruited to the silenced p21 gene promoter to cooperatively inhibit p21 gene transcription. Induction of p21<sup>WAF1</sup> gene upon human immunodeficiency virus 1 (HIV-1) infection benefits viral expression in macrophages. Here, we report that CTIP2 further abolishes Vpr-mediated stimulation of p21, thereby indirectly contributing to HIV-1 latency. Altogether, our results suggest that CTIP2 is a constitutive p21 gene suppressor that cooperates with SUV39H1 and histone methylation to silence the p21 gene transcription.

### Keywords

CTIP2; p21<sup>WAF1</sup>; SUV39H1; HIV-1

© 2009 Macmillan Publishers Limited All rights reserved

Correspondence: Professor O Rohr, U575, INSERM/Université de Strasbourg, 3 Rue Koeberlé, Strasbourg 67000, France. olivier.rohr@iutpa.u-strasbg.fr or Dr C Van Lint, Laboratory of Molecular Virology, Institut de Biologie et de Médecine Moléculaire (IBMM), University of Bruxelles (ULB), Gosselies, Belgium cvlint@ulb.ac.be.

<sup>7</sup>These authors equally contributed to this work.

<sup>8</sup>These authors equally contributed to this work.

Supplementary Information accompanies the paper on the *Oncogene* website (<http://www.nature.com/onc>)

## Introduction

The cyclin-dependent kinase inhibitor, CDKN1A/p21<sup>WAF1</sup> (p21), is a key cell cycle controller that is mainly regulated at the transcriptional level (Gartel and Radhakrishnan, 2005). Induction of p21 results in G1-, G2- (Niculescu *et al.*, 1998) or S-phase arrest (Ogryzko *et al.*, 1997; Radhakrishnan *et al.*, 2004). Both positive and negative regulations modulate p21 gene expression. A variety of cellular transcription factors, such as p53, Sp1 or C/EBP, stimulate p21 gene promoter activity (for review see Gartel and Tyner (1999)). However, little is known about the negative regulation of p21 (Gartel and Radhakrishnan, 2005). Previous studies have identified direct negative regulatory effects exerted by Myc and AP4 on the p21 gene promoter (Claassen and Hann, 2000; Gartel *et al.*, 2001; Jung *et al.*, 2008) and indirect effects through the inhibition of p53. Epigenetic modifications, such as DNA methylation and histone deacetylation, are crucial for p21 gene silencing (Suzuki *et al.*, 2000; Gartel and Tyner, 2002; Lagger *et al.*, 2003; Gartel and Radhakrishnan, 2005), but the underlying molecular mechanism through which the involved chromatin-modifying enzymes are recruited to the p21 gene promoter remain unclear. Although p21 has been known for some time to play an important part in cell cycle regulation and the pathogenesis of several disorders, including several cancers, p21 has been recently described as a pivotal facilitator of the human immunodeficiency virus 1 (HIV-1) life cycle in macrophages, a key target cell type in AIDS pathogenesis. HIV-1 infection activates p21 expression and forces a cell cycle arrest that is highly permissive for viral transcription in macrophages (Thierry *et al.*, 2004; Vazquez *et al.*, 2005). In hematopoietic cells, p21 expression is detrimental to HIV-1 replication (Zhang *et al.*, 2007). In addition, HIV-1 has been shown to reduce p21 gene expression in T cells (Clark *et al.*, 2000). In macrophages, HIV-1-induced p21 overexpression has been attributed to the HIV-1 Vpr protein. Vpr stimulates p21 gene transcription in cooperation with the cellular transcription factor Sp1, which binds to the p21 gene promoter (Amini *et al.*, 2004). Vpr has many other cellular effects (for review see Moon and Yang (2006)), including indirect DNA damages, which also favor G2 arrest and apoptosis (Schrofelbauer *et al.*, 2007). Moreover, p21 is required to sustain G2 arrest after DNA damage (Bunz *et al.*, 1998).

We have previously reported that the cellular cofactor COUP-TF-Interacting Protein 2 (CTIP2) represses HIV-1 gene transcription in microglial cells, the central nervous system-resident macrophages. In microglial cells, CTIP2 binds the HIV-1 promoter through Sp1, and recruits histone deacetylase (HDAC) and histone methyltransferase (HMT) activities to promote heterochromatic environment and HIV-1 transcriptional silencing (Marban *et al.*, 2005, 2007). The observation that CTIP2 can affect gene expression through HDAC and HMT recruitments to the viral promoter suggests that other genes might be targeted by similar mechanisms. CTIP2 has been observed to have many, sometimes apparently disparate, effects in a variety of cell types and biological systems, but little unifying mechanistic data have been reported. CTIP2 is expressed in the brain and the immune system (Leid *et al.*, 2004), and plays a major role in the development of corticospinal motor neuron axonal projections to the spinal cord (Arlotta *et al.*, 2005). In the SK-N-MC neuronal cell line, CTIP2 inhibits transcription of the cdk inhibitor p57KIP2 transcription (Topark-Ngarm *et al.*, 2006). Mostly described as a corepressor, CTIP2 participates in the activation of IL2 gene expression in CD4 + T lymphocytes (Cismasiu *et al.*, 2006). CTIP2 regulates both differentiation and survival of thymocytes, and is required for T-lymphocyte development. Thymocytes from CTIP2 KO mice are highly susceptible to apoptosis (Wakabayashi *et al.*, 2003b), but CTIP2 gene deletions or point mutations induce thymic lymphomas in gamma-irradiated mice (Wakabayashi *et al.*, 2003a). Recent studies confirmed that CTIP2 exerts anti-apoptotic activities in T cell lines (Grabarczyk *et al.*, 2007; Kamimura *et al.*, 2007). All these convergent data prompted us to investigate the impact of CTIP2 on the cell cycle, specifically in HIV-1-infected macrophages and microglial cells.

Here, we report that CTIP2 is a key transcriptional regulator of p21 gene expression. Recruited to the Sp1-binding sites of the p21 promoter, CTIP2 transcriptionally repressed constitutive p21 gene expression in cooperation with HDAC and HMT activities. Treatment with trichostatin A (TSA, a class-I and -II HDAC inhibitor) and with chaetocin (a specific inhibitor of the HMT SUV39H1) activated p21 gene promoter activity. Whereas SUV39H1 cooperated with CTIP2 to repress p21 gene transcription, chaetocin treatments induced cell cycle arrest. Interestingly, as p21 gene expression was enhanced upon HIV infection in macrophages and microglial cells, CTIP2 counteracted this Vpr-mediated effect and the related cell cycle arrest. CTIP2 and Vpr were shown to be recruited to the p21 promoter *in vivo*. However, CTIP2 overexpression displaced Vpr from the p21 gene promoter, thereby promoting p21 gene transcriptional silencing. Altogether, our results show histone methylation as an epigenetic modification involved in p21 transcriptional silencing, and suggest that CTIP2-mediated anti-HIV activity is a bimodal phenomenon. CTIP2 both recruits a repressive chromatin-modifying enzymatic complex to the HIV-1 promoter, as previously shown by our laboratory, and has an indirect effect on the cell cycle progression through p21 promoter repression.

## Results

### CTIP2 impairs constitutive p21 gene transcription

To assess the potential impact of CTIP2 on the transcriptional activity of the p21 gene promoter, we transfected microglial cells with a full-length p21 promoter–luciferase construct (p21-LUC) in the presence or not of CTIP2. Whereas overexpression of CTIP2 downregulated p21 gene transcription up to 80% (Figure 1a), knocking down CTIP2 strongly stimulated (up to sixfold) p21 promoter activity (Figure 1b and Supplementary Figures 1 and 6a). To evaluate p21 expression at the protein level, we performed immunodetection experiments using extracts from CTIP2 knocked down cells (Figure 1c, column 2) and control cellular extracts (Figure 1c, column 1). The p21 protein was barely detectable in the control cell extracts, but was strongly increased in CTIP2 knocked down cells (Figure 1c, columns 1 and 2).

These results showed that CTIP2 constitutively represses transcription of the p21 gene and its subsequent protein expression.

### CTIP2 is recruited to the p21 gene proximal promoter *in vivo* to inhibit p21 gene transcription

To examine the presence of CTIP2 on the p21 gene promoter *in vivo*, we performed chromatin immunoprecipitation (ChIP) experiments using microglial cells and a set of primers flanking the proximal Sp1 binding sites of the endogenous p21 promoter. As shown in Figure 1d, CTIP2 as well as Sp1 associated with the proximal region of the p21 promoter. We recently reported that Sp1 protein acts as an anchor for CTIP2 on the HIV-1 promoter (Marban *et al.*, 2005, 2007). As the p21 gene promoter harbors six Sp1-binding sites, we decided to map the Sp1 sites involved in CTIP2-mediated transcriptional repression by transfecting progressive 5'-truncated and mutated p21 reporter constructs. As shown in Figure 1e, 5'-truncations of the p21 promoter up to the Sp1-binding site region did not significantly impair CTIP2-mediated repression (Figure 1e, lanes 2–6). However, further deletion of the –246/–103 Sp1-binding sites (sites 1 and 2) not only abolished this repressive activity but also caused a 4.5-fold increase in luciferase activity (Figure 1e, compare lane 7 with lanes 2–6). Further mutations in the –103/+1 Sp1-binding sites (sites 3–6) did not change the CTIP2-mediated transcriptional effects observed with the –103 p21 promoter construct (data not shown). However, mutation of the Sp1 site 1 (Figure 1e, line 8), but not of the Sp1 site 2 (Figure 1e, line 9), impaired the CTIP2 repressive activity. Logically,

whereas CTIP2 knockdown activated the full-length p21 promoter activity, 5' deletion of the promoter region, including the Sp1 sites 1 and 2, abrogated this activation (Figure 1f, lane 3).

Altogether, both overexpression and knockdown experiments show that the CTIP2 cofactor negatively regulates p21 gene promoter activity through the Sp1-binding site 1 located 119 bp upstream of the initiation start site. Furthermore, these data and Supplementary Figure 3 suggest that Sp1 proteins bound to site 1 are involved in recruitment of CTIP2 to the p21 gene promoter.

### **CTIP2 cooperates with TSA-sensitive HDACs and with SUV39H1 to repress p21 expression**

We have recently shown that CTIP2 is part of a chromatin-modifying multienzymatic complex that includes HDAC1, HDAC2 and SUV39H1 (Marban *et al.*, 2007). To assess the potential role of these enzymes in p21 gene transcription, we transfected microglial cells with the full-length p21-LUC reporter plasmid. At 24-h post-transfection, cells were treated or not with TSA (Figure 2a). TSA treatment stimulated p21 gene promoter activity up to fourfold (Figure 2a, column 2), which is in agreement with the previously reported involvement of TSA-sensitive HDACs in the constitutive repression of p21 gene transcription (Murphy *et al.*, 1999; Sowa *et al.*, 1999). Furthermore, CTIP2 knockdown and TSA treatment synergistically activated p21 gene promoter activity up to 18-fold (Figure 2a, column 4). These data corroborate with the interactions among CTIP2, HDAC1 and HDAC2, which we have previously described (Marban *et al.*, 2007), and with the previously described HDAC1 recruitment to the p21 promoter through Sp1 association (Lagger *et al.*, 2003). Next, we focused on the potential role of SUV39H1 in p21 gene transcription. Treatments with increasing concentrations of chaetocin, a specific inhibitor of SUV39H1, activated p21 gene promoter activity in a dose-dependent manner (Figure 2b) and induced cell cycle arrest (Figure 2d and Supplementary Figure 5). Importantly, the level of trimethylation of histone H3 lysine 9 in the p21 promoter region decreased upon chaetocin treatment (Figure 2c), showing, in the context of the p21 promoter, the inhibitory effect of chaetocin on SUV39H1-mediated trimethylation. To further study the role of SUV39H1 in p21 gene repression, we investigated the recruitment of this HMT to the p21 gene promoter using ChIP assays. As shown in Figure 3a, SUV39H1 was constitutively associated with the p21 promoter *in vivo*. Functionally, SUV39H1 knockdown strongly activated the p21 promoter activity in a dose-dependent manner (Figure 3b and Supplementary Figure 6b). We have recently reported that CTIP2 interacts with SUV39H1 and favors its recruitment to the HIV-1 promoter (Marban *et al.*, 2007). To examine whether SUV39H1 cooperates with CTIP2 in p21 promoter repression, we performed CTIP2 and SUV39H1 knockdown and overexpression experiments in microglial cells expressing p21-promoter-reporter constructs (Figure 3c). Knocking down SUV39H1 expression caused a threefold stimulation of p21 gene promoter activity (Figure 3c, column 2), and the combined knockdown of both SUV39H1 and CTIP2 cooperated to stimulate p21 gene promoter activity up to ninefold (Figure 3c, column 4). Moreover, although overexpression of SUV39H1 alone only slightly repressed p21 gene promoter activity in a dose-dependent manner (Figure 3d, columns 2–4), the combined over-expression of both CTIP2 and SUV39H1 synergistically repressed p21 promoter activity up to 80% (Figure 3d, columns 6–8). This functional repressive cooperation supports the model that CTIP2 mediates recruitment of SUV39H1 to the p21 promoter, as we have observed in the context of the HIV-1 promoter (Marban *et al.*, 2007). Altogether, these results show the involvement of SUV39H1 and the cooperation of CTIP2 and SUV39H1 in p21 gene transcriptional silencing and in cell cycle control.

### **p21 gene transcription is upregulated upon HIV-1 infection in primary 'microglial-like' cells**

Infection of macrophages by HIV-1 activates p21 mRNA production and promotes G2/M cell cycle arrest. Both events seem to favor HIV-1 replication (Thierry *et al.*, 2004; Vazquez *et al.*, 2005). To examine whether p21 expression is modified in microglial cells, we infected human primary macrophages and micro-glial-like cells with the HIV-1 Bal isolate and quantified p21 mRNA by quantitative reverse transcriptase PCR (Figure 4a). Given that the fluctuations of the p21 mRNA level in non-infected cells may result from the culture conditions, p21 mRNA production was stimulated by HIV-1 infection in primary macrophages, as previously described (Vazquez *et al.*, 2005). Interestingly, the same range of activation was observed in infected primary microglial-like cells, suggesting the need for p21-induced events for efficient HIV-1 expression in microglial cells too. More importantly, these results suggest that p21 induction may be a good target for transcriptional silencing factors involved in HIV-1 latency. Thus, we logically looked at CTIP2-mediated activity in both HIV-1-infected primary monocyte-derived cell types.

### **CTIP2 represses HIV-1 replication in human primary macrophages and microglial-like cells**

To investigate CTIP2 function in HIV-1-infected primary cells, we transfected primary macrophages and primary macrophage-derived microglial-like cells with a complete HIV-1 infectious provirus (pNL4-3) in the presence or not of CTIP2 overexpression. As shown in Figure 4b, CTIP2 overexpression repressed HIV-1 replication up to 70% in both human primary cell types tested. These results confirmed, in cultured primary cells, the repressive activity of CTIP2 previously observed in a microglial cell line. Moreover, these results prompted us to investigate, in the context of HIV-1 infection, the impact of CTIP2 on p21 gene expression and the resulted cell cycle status.

### **CTIP2 impairs Vpr-mediated stimulation of p21 gene transcription and the resulting cell cycle arrest**

To determine whether CTIP2 impacts Vpr-induced cell cycle arrest, we examined the cell cycle status of doxycycline-inducible Vpr-expressing cells (Yoshizuka *et al.*, 2005) with or without CTIP2 overexpression. Quantification of DNA content by flow cytometry confirmed the ability of Vpr to induce G2/M cell cycle arrest (Figure 5a, panel 3). Whereas the cell cycle status was slightly impacted by CTIP2 overexpression in the absence of Vpr (Figure 5a, panel 2), Vpr-induced G2/M block was completely abolished (Figure 5a, panel 4). Vpr, CTIP2 and p21 expression were verified by western blot experiments (Figure 5a, lower panels). Vpr-induced cell cycle arrest could be a consequence of p21 gene transcriptional activation. As shown in Figures 5b and c, Vpr expression stimulated p21 gene promoter activity and subsequent p21 protein expression. To examine whether Vpr directly affected p21 gene promoter activity *in vivo*, we performed ChIP experiments targeting the proximal region of the promoter. As shown in Figure 5d, Vpr was found associated with the p21 gene proximal promoter *in vivo*. Interestingly, overexpression of CTIP2 repressed Vpr-induced p21 gene transcription (Figure 5e, columns 3–5) and p21 protein expression (Figure 5f), as suggested by the ability of CTIP2 to impair Vpr-mediated cell cycle arrest. To examine the recruitment of CTIP2 and Vpr to the p21 promoter, we performed additional ChIP experiments. As shown in Figure 5g, as Vpr expression slightly affected CTIP2 recruitment to the p21 promoter proximal region (Figure 5g, column 8), CTIP2 over-expression impaired Vpr association with the same region (Figure 5g, column 12). As a control, expression of Vpr and CTIP2 did not significantly modify Sp1 binding to the GC-rich regions of the p21 promoter (Figure 5g, columns 2–4). To assess CTIP2-mediated relocation of Vpr in microglial cells, we observed CTIP2 and Vpr cellular localizations by confocal microscopy. As Vpr–GFP (green fluorescent protein) alone localized in the nucleus and the cytoplasm of the cells (Figure 6, panels 1 and 2), coexpression of red fluorescent protein (RFP)–CTIP2 with Vpr–GFP relocated Vpr in



characteristic CTIP2-induced ball-like structures (Figure 6, panels 5–7). To visualize microglial cell nuclei, genomic DNA was stained (Figure 6, panels 2–7). As shown, CTIP2 and Vpr colocalized in the same structures (Figure 6, panel 7), suggesting that CTIP2 may displace Vpr from the p21 promoter to subnuclear structures. As a control, GFP–SUV39H1 expression alone did not affect Vpr localization (Supplementary Figure 7). Altogether, these results revealed CTIP2 as a major p21 gene transcriptional silencer and a potent anti-Vpr cellular factor.

## Discussion

In addition to its role in DNA damage response, p21 is involved in differentiation, senescence, tumor suppression and HIV-1 expression (Gartel and Tyner, 2002; Thierry *et al.*, 2004; Vazquez *et al.*, 2005).

Here, we show that CTIP2 is a constitutive transcriptional repressor of p21 gene transcription. The observed presence of endogenous CTIP2 on the p21 gene promoter *in vivo* was correlated with the undetectable level of the p21 protein under basal conditions. Moreover, the activation of p21 expression in CTIP2 knocked down cells provided further evidence for the constitutive repressive activity of CTIP2. As we have previously shown that CTIP2 is recruited to the HIV-1 promoter through Sp1 (Marban *et al.*, 2005), we decided to examine the Sp1-binding sites of the p21 promoter involved in CTIP2-mediated transcriptional repression. The Sp1-binding site 1 (–119 bp region) seemed necessary for CTIP2-mediated repression and for its anchorage at the p21 promoter by Sp1 proteins (Supplementary Figure 3). The association of CTIP2 with HDAC1 and HDAC2 has been well documented (Marban *et al.*, 2007) (Cismasiu *et al.*, 2005; Topark-Ngarm *et al.*, 2006). Thus, the surprising stimulation of the –103/+1 p21 promoter construct mediated by CTIP2 overexpression may be explained by an artificial titration of HDAC1 that would favor p53-mediated transactivation of p21 expression, as suggested by Lagger *et al.*, 2003. The fact that CTIP2 knockdown did not affect the –103/+1 transcriptional activity further supports this hypothesis. We did not observe significant CTIP2-mediated modification of p53 expression, localization, phosphorylation or acetylation (Supplementary Figure 2b and data not shown). However, CTIP2 repressed p53-dependent activation of the full-length p21 gene promoter (Supplementary Figure 2a), suggesting that CTIP2 would need to be associated with the p21 promoter to inhibit p53. To further explore in molecular detail the role of CTIP2 in p21 repression, we focused on CTIP2-associated enzymatic activities. As HDAC inhibitors have been previously shown to favor p21 expression (for review see Ocker and Schneider-Stock (2007)), we limited our investigations in this field. As previously shown, we show that the inhibitor TSA induced p21 expression. Moreover, we observed that CTIP2 knockdown cooperated with TSA treatment to stimulate the p21 promoter. These results revealed that the functional cooperation of CTIP2 with TSA-sensitive HDAC (here HDAC1 and HDAC2) is not limited to the HIV-1 promoter (Marban *et al.*, 2007) and confirmed the CTIP2-mediated recruitment of the enzymes to the targeted promoters. More interesting was the stimulation observed after Chaetocin treatment. The SUV39H1 inhibitor (Greiner *et al.*, 2005) strongly stimulated p21 gene transcription and induced cell cycle arrest. These observations were consistent with an observed decrease in methylation of the histone H3 lysine 9 at the p21 promoter confirming an effective inhibition of endogenous SUV39H1 activity. In line with these observations, we found endogenous SUV39H1 associated with the p21 promoter *in vivo* and we showed its functional cooperation with CTIP2 in p21 gene transcriptional silencing. These results provide the first evidence of SUV39H1 involvement in p21 gene transcriptional silencing. In addition, they also suggest that chaetocin could be used as an anti-proliferative pharmacological tool. Recently, chaetocin has been proposed as a promising anti-myeloma agent (Isham *et al.*, 2007). As previously suggested for HDAC inhibitors, chaetocin anti-myeloma activity has been linked to oxidative stress (Pei *et al.*,

2004). Our results suggest that pro-apoptotic activity of chaetocin may be mediated, at least in part, by inhibition of SUV39H1 HMT activity at the p21 gene promoter. We report that SUV39H1 and CTIP2 cooperate to silence p21 gene transcription and thereby favor cell cycle progression. The previously reported anti-apoptotic activities of CTIP2 have been attributed to its involvement in the maintenance of genomic integrity (Kamimura *et al.*, 2007) and in the modulation of intrinsic apoptotic pathways (Grabarczyk *et al.*, 2007). Although our results show that CTIP2 impairs p21 gene expression, the regulatory link between the potential anti-apoptotic function of CTIP2 and p21 needs further investigations.

As HIV-1 infection reduces p21 gene expression in T lymphocytes (Clark *et al.*, 2000), infection of macrophages stimulates p21 expression and induces cell cycle arrest (Vazquez *et al.*, 2005). Interestingly, G2 arrest favors HIV-1 expression as a result of nuclear factor  $\kappa$ B, C-Jun and CREB-binding protein recruitment to the viral promoter (Thierry *et al.*, 2004). However, the physiological mechanism underlying p21-mediated facilitation of HIV-1 expression needs to be further clarified in non-dividing cells. Mechanistically, HIV-1-induced p21 expression and cell cycle arrest have been attributed to HIV-1 Vpr functions. Apart from CTIP2 repression of HIV-1 replication in human primary macrophage and microglial cells, our results showed that CTIP2 abrogates Vpr-induced cell cycle arrest, suggesting that CTIP2 may also impact Vpr-mediated transcriptional activation of the p21 gene. Vpr has been described to collaborate with the cellular Sp1 transcription factor to stimulate p21 promoter in human astrocyte (Amini *et al.*, 2004). In microglial cells, we observed a Vpr-mediated transcriptional stimulation of p21 gene expression as a result of Vpr recruitment at the endogenous p21 gene promoter *in vivo*. Interestingly, CTIP2 repressed Vpr-mediated transcriptional activation of p21 expression. Our ChIP assays suggest that CTIP2 antagonises Vpr binding to the p21 gene promoter and thereby counteracts Vpr function. However, as Vpr-induced G2 arrest may be explained by multiple molecular mechanisms, including association with the Cul4–DDB1 E3 ligase complex (Le Rouzic *et al.*, 2007; Andersen *et al.*, 2008), more investigations need to be engaged to determine all CTIP2-impacted functions of Vpr (Supplementary Figure 4).

Altogether, CTIP2 cooperates with SUV39H1 and HDACs to suppress endogenous and Vpr-induced p21 gene expression.

## Materials and methods

### Plasmids

Constructs used in this study have been described previously: pcDNA3, pFLAG-CTIP2, pNL4. 3, pVSV.G and pRFPCTIP2 (Marban *et al.*, 2005), pMyc-SUV39H1, pshRNASUV39H1 (Schotta *et al.*, 2004), pshRNA-CTIP2 (Marban *et al.*, 2007), pHA-Vpr and the different deletion mutants of p21-LUC (Koutsodontis *et al.*, 2002; Amini *et al.*, 2004).

### Cell culture

The human microglial cell line (Janabi *et al.*, 1995) and HEK 293T cell line were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum and 100 U/ml penicillin–streptomycin. Primary macrophages and monocyte-derived microglia-like cells were isolated, prepared and cultured as described (Leone *et al.*, 2006). Inducible Vpr-expressing HEK cells were described (Yoshizuka *et al.*, 2005).

### Cell cycle analysis

Cell cycle status has been determined by propidium iodide DNA staining and flow cytometry analyses. Briefly, trypsinized cells were washed and resuspended in propidium

iodide staining solution for 30 min. Flow cytometric analysis was performed in a FACScalibur instrument (Becton Dickinson, San Jose, CA, USA). Cell cycle analysis was performed using CellQuest software (Becton Dickinson).

### SDS–polyacrylamide gel electrophoresis and western blot analysis

Sodium dodecyl sulfate polyacrylamide gel electrophoresis was performed using standard techniques. Proteins were detected using antibodies directed against the FLAG epitope (M2 mouse monoclonal from Sigma, St Louis, MO, USA), CTIP2 (Santa Cruz, Santa Cruz, CA, USA), p21 (Santa Cruz), the HA epitope (Covance, Princeton, NJ, USA) and  $\beta$ -actin (Sigma). Proteins were visualized by chemiluminescence using the Super Signal Chemiluminescence Detection System (Pierce, Rockford, IL, USA).

### Luciferase assays

Microglial cells cultured in 48-well plates were transfected with the indicated vectors and the *Renilla* control vector using the calcium phosphate co-precipitation method. Two days later, cells were collected and firefly luciferase activity was determined using the Dual-Glo Luciferase Assay System (Promega, Madison, WI, USA) and normalized to the *Renilla* luciferase activity. Values correspond to an average of at least three independent experiments performed in duplicates.

### HIV-1 infection and viral replication

Macrophages and microglial-like cells were cultured and prepared as previously described (Leone *et al.*, 2006). Cultured in 24-well plates, cells were transfected using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) with the complete HIV-1 infectious molecular clone pNL4-3 and the expression plasmids, as indicated. Total amounts of DNA were normalized with the corresponding empty vector. For infection experiments, cells were infected with HIV-1 Bal. HIV-1 replication was monitored as described previously (Leone *et al.*, 2006). Values correspond to an average of at least three independent experiments carried out in duplicates.

### Immunofluorescence staining and confocal microscopy observation

Microglial cells cultured in 24-well plates were transfected using Lipofectamine 2000 reagent with pRFP-CTIP2 and pVpr-GFP expression vectors. Cells were fixed and permeabilized as previously described (Rohr *et al.*, 2003). The coverslips were then incubated for 10 min at room temperature with TOPRO3 (Molecular Probes, Eugene, OR, USA). The stained cells were analysed by confocal microscopy using a Zeiss laser scanning microscope (Zeiss, Jena, Germany; model 510 inverted) equipped with a Planapo oil ( $\times 63$ ) immersion lens (numerical aperture = 1,4).

### Chromatin immunoprecipitation assays

The HEK 293T and microglial cells cultured in 100-mm diameter dishes were transfected (or not as indicated) using the calcium phosphate co-precipitation method with the indicated vectors. ChIP assays were performed using the ChIP assay kit (Milipore Inc., Billerica, MA, USA) 48-h post-transfection. The primary antibodies used for ChIP were as follows: anti-CTIP2 (Abcam), anti-Sp1 (Milipore Inc.), anti-HA (Covance), anti-triMeK9/H3, anti-SUV39H1 (Abcam, Cambridge, UK). Treatments with chaetocin were performed at a final concentration of 200 nM for 24 h. Immunoprecipitated DNA was subjected to real-time PCR quantification and normalized to the non-specific glyceraldehyde 3-phosphate dehydrogenase promoter enrichment.



## mRNA Quantification

The RNAs from HIV-1 Bal-infected cells were extracted with RNeasy Plus Mini Kit (Qiagen, Germantown, MD, USA) and retrotranscription was performed with Superscript III (Invitrogen). cDNA were quantified and normalized to the  $\beta$ -actin mRNA level.

## Acknowledgments


We thank Dr D Kardassis for providing us with p21-LUC plasmids and Dr Yannick Goumon for his technical support. This work was supported by the Institut National de la Santé et de la Recherche Médicale (INSERM), by grants from the Agence Nationale de Recherches sur le SIDA (ANRS) to OR and CVL, from Sidaction to OR and TC and from the French Ministry of Research ('ACI JC 5364' to OR and doctoral grant to TC and SS) The work in CVL's laboratory was supported by grants from the 'Fonds National de la Recherche Scientifique' (FNRS, Belgium), the Télévie-Program of the FNRS, from the 'Action de Recherche concertée du Ministère de la Communauté Française' (ULB, ARC program no. 04/09-309), from the Internationale Brachet Stiftung (IBS), from the Région Wallonne-Commission Européenne FEDER (Intergenes Project, Interreg III program) and from the Theyskens-Mineur Foundation. CVL is 'Directeur de Recherches' of the FNRS. This work was supported by NIH to BES.

## References

- Amini S, Saunders M, Kelley K, Khalili K, Sawaya BE. Interplay between HIV-1 Vpr and Sp1 modulates p21(WAF1) gene expression in human astrocytes. *J Biol Chem*. 2004; 279:46046–46056. [PubMed: 15302882]
- Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. *Exp Mol Pathol*. 2008; 85:2–10. [PubMed: 18514189]
- Arlotta P, Molyneaux BJ, Chen J, Inoue J, Kominami R, Macklis JD. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. *Neuron*. 2005; 45:207–221. [PubMed: 15664173]
- Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science*. 1998; 282:1497–1501. [PubMed: 9822382]
- Cismasiu VB, Adamo K, Gecewicz J, Duque J, Lin Q, Avram D. BCL11B functionally associates with the NuRD complex in T lymphocytes to repress targeted promoter. *Oncogene*. 2005; 24:6753–6764. [PubMed: 16091750]
- Cismasiu VB, Ghanta S, Duque J, Albu DI, Chen HM, Kasturi R, et al. BCL11B participates in the activation of IL2 gene expression in CD4+ T lymphocytes. *Blood*. 2006; 108:2695–2702. [PubMed: 16809611]
- Claassen GF, Hann SR. A role for transcriptional repression of p21CIP1 by c-Myc in overcoming transforming growth factor beta -induced cell-cycle arrest. *Proc Natl Acad Sci USA*. 2000; 97:9498–9503. [PubMed: 10920185]
- Clark E, Santiago F, Deng L, Chong S, de La Fuente C, Wang L, et al. Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. *J Virol*. 2000; 74:5040–5052. [PubMed: 10799578]
- Gartel AL, Radhakrishnan SK. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. *Cancer Res*. 2005; 65:3980–3985. [PubMed: 15899785]
- Gartel AL, Tyner AL. The growth-regulatory role of p21 (WAF1/CIP1). *Exp Cell Res*. 1999; 246:280–289. [PubMed: 9925742]
- Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. *Mol Cancer Ther*. 2002; 1:639–649. [PubMed: 12479224]
- Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. *Proc Natl Acad Sci USA*. 2001; 98:4510–4515. [PubMed: 11274368]
- Grabarczyk P, Przybylski GK, Depke M, Volker U, Bahr J, Assmus K, et al. Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells. *Oncogene*. 2007; 26:3797–3810. [PubMed: 17173069]

- Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. *Nat Chem Biol.* 2005; 1:143–145. [PubMed: 16408017]
- Isham CR, Tibodeau JD, Jin W, Xu R, Timm MM, Bible KC. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress. *Blood.* 2007; 109:2579–2588. [PubMed: 17090648]
- Janabi N, Peudener S, Heron B, Ng KH, Tardieu M. Establishment of human microglial cell lines after transfection of primary cultures of embryonic microglial cells with the SV40 large T antigen. *Neurosci Lett.* 1995; 195:105–108. [PubMed: 7478261]
- Jung P, Menssen A, Mayr D, Hermeking H. AP4 encodes a c-MYC-inducible repressor of p21. *Proc Natl Acad Sci USA.* 2008; 105:15046–15051. [PubMed: 18818310]
- Kamimura K, Mishima Y, Obata M, Endo T, Aoyagi Y, Kominami R. Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages. *Oncogene.* 2007; 26:5840–5850. [PubMed: 17369851]
- Koutsodontis G, Moustakas A, Kardassis D. The role of Sp1 family members, the proximal GC-rich motifs, and the upstream enhancer region in the regulation of the human cell cycle inhibitor p21WAF-1/Cip1 gene promoter. *Biochemistry.* 2002; 41:12771–12784. [PubMed: 12379120]
- Laguerre G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. *Mol Cell Biol.* 2003; 23:2669–2679. [PubMed: 12665570]
- Le Rouzic E, Belaidouni N, Estrabaud E, Morel M, Rain JC, Transy C, et al. HIV1 Vpr arrests the cell cycle by recruiting DCAF1/VprBP, a receptor of the Cul4-DDB1 ubiquitin ligase. *Cell Cycle.* 2007; 6:182–188. [PubMed: 17314515]
- Leid M, Ishmael JE, Avram D, Shepherd D, Fraulob V, Dolle P. CTIP1 and CTIP2 are differentially expressed during mouse embryogenesis. *Gene Expr Patterns.* 2004; 4:733–739. [PubMed: 15465497]
- Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, et al. Characterization of human monocyte-derived micro-glia-like cells. *Glia.* 2006; 54:183–192. [PubMed: 16807899]
- Marban C, Redel L, Suzanne S, Van Lint C, Lecestre D, Chasserot-Golaz S, et al. COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells. *Nucleic Acids Res.* 2005; 33:2318–2331. [PubMed: 15849318]
- Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, et al. Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. *EMBO J.* 2007; 26:412–423. [PubMed: 17245431]
- Moon HS, Yang JS. Role of HIV Vpr as a regulator of apoptosis and an effector on bystander cells. *Mol Cells.* 2006; 21:7–20. [PubMed: 16511342]
- Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. *Genes Dev.* 1999; 13:2490–2501. [PubMed: 10521394]
- Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. *Mol Cell Biol.* 1998; 18:629–643. [PubMed: 9418909]
- Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. *Int J Biochem Cell Biol.* 2007; 39:1367–1374. [PubMed: 17412634]
- Ogryzko VV, Wong P, Howard BH. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. *Mol Cell Biol.* 1997; 17:4877–4882. [PubMed: 9234744]
- Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. *Clin Cancer Res.* 2004; 10:3839–3852. [PubMed: 15173093]
- Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegbarth A, Kandel ES, Tyner AL, et al. Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. *Oncogene.* 2004; 23:4173–4176. [PubMed: 15048076]


- Rohr O, Lecestre D, Chasserot-Golaz S, Marban C, Avram D, Aunis D, et al. Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. *J Virol*. 2003; 77:5415–5427. [PubMed: 12692243]
- Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. *Genes Dev*. 2004; 18:1251–1262. [PubMed: 15145825]
- Schrofelbauer B, Hakata Y, Landau NR. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. *Proc Natl Acad Sci USA*. 2007; 104:4130–4135. [PubMed: 17360488]
- Sowa Y, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T. Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor. *Cancer Res*. 1999; 59:4266–4270. [PubMed: 10485470]
- Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. *Int J Cancer*. 2000; 88:992–997. [PubMed: 11093826]
- Thierry S, Marechal V, Rosenzweig M, Sabbah M, Redeuilh G, Nicolas JC, et al. Cell cycle arrest in G2 induces human immunodeficiency virus type 1 transcriptional activation through histone acetylation and recruitment of CBP, NF-kappaB, and c-Jun to the long terminal repeat promoter. *J Virol*. 2004; 78:12198–12206. [PubMed: 15507606]
- Topark-Ngarm A, Golonzhka O, Peterson VJ, Barrett B Jr, Martinez B, Crofoot K, et al. CTIP2 associates with the NuRD complex on the promoter of p57KIP2, a newly identified CTIP2 target gene. *J Biol Chem*. 2006; 281:32272–32283. [PubMed: 16950772]
- Vazquez N, Greenwell-Wild T, Marinos NJ, Swaim WD, Nares S, Ott DE, et al. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. *J Virol*. 2005; 79:4479–4491. [PubMed: 15767448]
- Wakabayashi Y, Inoue J, Takahashi Y, Matsuki A, Kosugi-Okano H, Shinbo T, et al. Homozygous deletions and point mutations of the Rit1/Bcl11b gene in gamma-ray induced mouse thymic lymphomas. *Biochem Biophys Res Commun*. 2003a; 301:598–603. [PubMed: 12565905]
- Wakabayashi Y, Watanabe H, Inoue J, Takeda N, Sakata J, Mishima Y, et al. Bcl11b is required for differentiation and survival of alpha beta T lymphocytes. *Nat Immunol*. 2003b; 4:533–539. [PubMed: 12717433]
- Yoshizuka N, Yoshizuka-Chadani Y, Krishnan V, Zeichner SL. Human immunodeficiency virus type 1 Vpr-dependent cell cycle arrest through a mitogen-activated protein kinase signal transduction pathway. *J Virol*. 2005; 79:11366–11381. [PubMed: 16103188]
- Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. *J Clin Invest*. 2007; 117:473–481. [PubMed: 17273559]

**Figure 1.**


Associated with the p21 proximal promoter region *in vivo*, COUP-TF-interacting protein 2 (CTIP2) impairs constitutive p21 gene transcription through the proximal -246/-103 Sp1-binding sites. Microglial cells (**a** and **b**) and 293T cells (**c**) were transfected with the indicated amounts of vectors in the presence of the p21-Luc plasmid. Luciferase activities (**a** and **b**) are presented relative to the activity of the p21-LUC cotransfected with the control empty vector. The protein levels (**c**) were accessed by western blot with the indicated antibodies 48-h post-transfection. (**d**) To detect association of CTIP2 and Sp1 with the p21 promoter, ChIP (chromatin immunoprecipitation) experiments were performed in microglial

cells with the indicated antibodies. Immunoprecipitated DNA was subjected to real-time PCR quantification with primers targeting the endogenous p21 promoter proximal region. Specific enrichments of the p21 promoter in the immunoprecipitated material were normalized to enrichments in non-specific glyceraldehyde 3-phosphate dehydrogenase DNA and are presented relative to the control. (e and f) Microglial cells were transfected with the p21-LUC constructs in the presence or absence of the pFlag-CTIP2 or pShRNA-CTIP2 plasmids, as indicated. Luciferase assays were performed 48-h post-transfection. Results are presented relative to the basal level of each p21-LUC constructs taken as one.




**Figure 2.**


Trichostatin A (TSA) and chaetocin stimulate p21 gene transcription. **(a, b)** Microglial cells were transfected with the p21-LUC reporter plasmid in the presence or absence of pSuper-shRNA-CTIP2, as indicated. At 24-h post-transfection, cells were treated with 450  $\mu$ M TSA or the indicated amount of chaetocin for 24 h and assessed for LUC activity. **(c)** Microglial cells were treated or not with 200 nM of chaetocin and subjected to ChIP (chromatin immunoprecipitation) experiments with anti-H3 trimethylated lysine 9. Immunoprecipitated DNA was subjected to real-time PCR quantification with primers targeting the endogenous p21 promoter proximal region. Specific enrichment of the p21 promoter in the immunoprecipitated material were normalized to enrichments in nonspecific glyceraldehyde 3-phosphate dehydrogenase DNA and presented relative to the control. **(d)** Microglial cells were treated with the indicated amount of chaetocin for 24 h before being assessed for cell cycle status by flow cytometry.

**Figure 3.**


COUP-TF-interacting protein 2 (CTIP2) cooperates with SUV39H1 to repress p21 gene transcription. **(a)** ChIP (chromatin immunoprecipitation) experiments were performed in microglial cells with the indicated antibodies. Immunoprecipitated DNA was subjected to real-time PCR quantification with primers targeting the endogenous p21 promoter proximal region. Specific enrichment of the p21 promoter in the immunoprecipitated material were normalized to enrichments in non-specific glyceraldehyde 3-phosphate dehydrogenase DNA and presented relative to the control. **(b–d)** Microglial cells were transfected with the p21-LUC reporter plasmid in the presence or absence of the indicated vectors. LUC assays were performed 48-h post-transfection and results presented relative to the basal level.

**Figure 4.**

As P21 gene expression is upregulated by human immunodeficiency virus 1 (HIV-1) infection, COUP-TF-interacting protein 2 (CTIP2) inhibits HIV-1 replication in human primary macrophages and microglial-like cells. **(a)** RNAs from HIV-1/Bal-infected cells were extracted and assessed for p21 mRNA expression. Inductions at each time points are presented relative to the control glyceraldehyde 3-phosphate dehydrogenase level. **(b)** Cells were transfected with HIV-1 pNL4-3 in the presence or absence (control cells) of the Flag-CTIP2 expression vector. HIV-1 reverse transcriptase activity was assessed 24-, 48- and 72-h post-transfection. Inhibition of HIV-1 replication is presented relative to the reverse transcriptase (RT) activity detected with the HIV-1-infected control cells. RT activity in control cells (without Flag-CTIP2) varied between 0 and 197 pg/ml.

**Figure 5.**

COUP-TF-interacting protein 2 (CTIP2) impairs Vpr-mediated stimulation of p21 gene transcription and the resulting cell cycle arrest. **(a)** 293T cells inducible for HIV-1 Vpr expression, were transfected with the Flag-CTIP2 expression vector or the control vector 24 h before being treated with doxycyclin. Cell cycle status was assessed by flow cytometry. Controls of Vpr, CTIP2 and p21 expressions are presented. Microglial cells **(b)** and 293 T cells **(c)** and **(f)** were transfected with the indicated amounts of expression vectors in the presence of the p21-Luc plasmid. Luciferase activities **(b)** and **(e)** are presented relative to the activity of the p21-LUC complemented by the control empty vector. Protein levels **(c)** and **(f)** were assessed by western blot using the indicated antibodies 48-h post-transfection. **(d)** and **(g)** 293T cells were transfected or not with the HA-Vpr and the Flag-CTIP2 expression vectors 48 h before being processed for ChIP (chromatin immunoprecipitation) assays. Immunoprecipitated DNA was subjected to real-time PCR quantification with primers targeting the endogenous p21 promoter proximal region. Specific enrichments of the p21 promoter in the immunoprecipitated material were normalized to enrichments in non-specific glyceraldehyde 3-phosphate dehydrogenase DNA and presented relative to the control.



**Figure 6.** COUP-TF-interacting protein 2 (CTIP2) relocates Vpr to subnuclear structures. Microglial cells were transfected with pVpr-GFP alone (panels 1, 2 and 3) or together with pRFP-CTIP2 plasmid (panels 4–10). Cells were fixed 24-h post-transfection and confocal analysis was performed.